Economics
HDx therapy delivers meaningful and relevant innovation for dialysis patients and opportunities to optimize care costs for providers and systems.
While HDx therapy may offer the potential to improve access to care and to help improve the effectiveness and quality of care, HDx therapy may simultaneously offer dialysis service providers and healthcare systems alike the opportunity to reduce the total cost of care.1,2
Importance of economics
A reduction in hospitalization and medication usage, may significantly reduce the total cost of care to a Payer and/or Provider.
Bunch A, Sanchez R, Nilsson LG, et al. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry.
Hospitalization length of stay may be reduced when prescribing HDx therapy enabled by Theranova dialyzer compared to conventional hemodialysis.3
Ariza JG, Walton SM, Suarez AM, et al. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia.
This analysis shows that HDx therapy statistically and significantly reduces hospitalization days and lowers doses of medications (including those used in-center), in a real-world setting over a period of two years.4
Blackowicz MJ, Falzon L, Beck W, et al. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: a post hoc evaluation of a randomized clinical trial in the United States.
In this post-hoc analysis of a randomized clinical trial, HDx therapy with Theranova dialyzer was associated with lower healthcare costs than standard high-flux HD. Theranova dialyzer is associated with a reduced hospitalization rate per patient year and is expected to be a cost-saving therapy, based on this significant reduction in hospitalization events.2
Molano AP, Hutchison CA, Sanchez R, et al. Medium cut-off versus high-flux hemodialysis membranes and clinical outcomes: a cohort study using inverse probability treatment weighting.
This cohort study showed that patients treated with the MCO membrane had lower rates of hospitalization and cardiovascular events compared with patients treated with high-flux membranes. These data support the hypothesis that increased clearance of pro-inflammatory middle molecules could reduce the occurrence of chronic inflammation, atherosclerosis, structural heart disease and immunodeficiency.4
Are you interested in learning more?
Contact Vantive to learn more about HDx therapy enabled by Theranova dialyzer.
Important Safety Information
Indications for Use: THERANOVA dialyzers are indicated for treatment of chronic and acute renal failure by Hemodialysis
Caution: Do not use THERANOVA dialyzers for HDF (hemodiafiltration) or HF (hemofiltration) due to higher permeability of larger molecular weight proteins such as albumin.
For safe and proper use of the device, please refer to the Instructions for Use.
Vantive, HDx, MCO and Theranova are trademarks of Vantive Health LLC or its affiliates.
References
-
Ariza JG, Walton SM, Suarez AM, et al. An initial evaluation of expanded haemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial. 2021;25(5):621-627.
-
Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic evaluation of expanded haemodialysis with the Theranova 400 dialyzer: a post hoc evaluation of a randomized clinical trial in the United States. Hemodial Int. 2022;26(3):449-455.
-
Bunch A, Sanchez R, Nilsson LG, et al. Medium cut-off dialyzers in a large population of haemodialysis patients in Colombia: COREXH registry. Ther Apher Dial. 2021;25(1):33-43.
-
Molano AP, Hutchison CA, Sanchez R, et al. Medium cutoff versus high-flux haemodialysis membranes and clinical outcomes: A cohort study using inverse probability treatment weighting. Kidney Medicine. 2022;4(4)100431.